

TOPT80"6695E860




FIG.1A

102180-6695660




FIG.1B




FIG.1C




FIG.2A




FIG.2B




FIG.2C




FIG.2D




FIG. 3




FIG. 4





FIG. 6



■ 5.0 µg; x 0.5 µg; △ 0.167 µg; □ 0.05 µg; ◇ 0.017 µg;
 ▲ 50 µg; ◆ 16.7 µg; ◻ 0.005 µg Vij:gD DNA; ○ saline

FIG. 5




FIG. 7

| Group ^a | Survivors/ Total (%) | Mean Day to Death | Paralyzed/ Total (%) | Vaginal Virus Titer ^b | | |
|--------------------|-------------------------|----------------------|-------------------------|----------------------------------|------------|------------|
| | | | | Day 2 ^c | Day 4 | Day 6 |
| Vaccine, 10 µg | 8/10 (80) | 12.5 ± 0.7 | 5/10 (50) | 3.8 ± 1.9 | 2.3 ± 1.2 | <1.5 ± 0.0 |
| Vaccine, 100 µg | 10/10 (100)† | >21 | 0/10 (0)* | 3.0 ± 1.3Ø | 2.0 ± 0.7† | <1.5 ± 0.0 |
| Placebo | 6/10 (60) | 14.8 ± 4.0 | 8/10 (80) | 5.0 ± 2.3 | 3.1 ± 1.4 | 1.6 ± 0.3 |

^a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

^b Log₁₀ cell culture infections doses per ml, determined from vaginal swabs.

^c After virus inoculation.

* P<0.001.

† P=0.08, Ø P=0.06.

FIG. 8




FIG. 9




FIG.10A




FIG.10B




FIG.11




FIG.12




FIG.13A




FIG.13B

FOI b6 b7C b7E b7F b7G b7H b7I b7J b7K b7L b7M b7N b7O b7P b7Q b7R b7S b7T b7U b7V b7W b7X b7Y b7Z b8 b8A b8B b8C b8D b8E b8F b8G b8H b8I b8J b8K b8L b8M b8N b8O b8P b8Q b8R b8S b8T b8U b8V b8W b8X b8Y b8Z b9 b9A b9B b9C b9D b9E b9F b9G b9H b9I b9J b9K b9L b9M b9N b9O b9P b9Q b9R b9S b9T b9U b9V b9W b9X b9Y b9Z




FIG.14A




FIG.14B




FIG.15A




FIG.15B